Payment overview · 2025
General Payments
$5,813.53
181 reported records · 27 companies
Healthcare provider profile · identity verified
Luay S Marji, MD
Allopathic & Osteopathic Physicians|Internal Medicine · YONKERS, NY · NPI 1477532828
Verified facts
What the public records show
CMS Open Payments records show Luay S Marji, MD received $5,813.53 in general payments during 2025 across 181 reported records.
ABBVIE INC. accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Verquvo, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $793.90 | 13.7% | 27 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $761.85 | 13.1% | 29 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $752.30 | 12.9% | 18 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $437.62 | 7.5% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $315.06 | 5.4% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $286.69 | 4.9% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $240.47 | 4.1% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $229.14 | 3.9% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $224.14 | 3.9% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $199.98 | 3.4% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $186.79 | 3.2% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $132.47 | 2.3% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $131.44 | 2.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $126.44 | 2.2% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $123.82 | 2.1% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $117.01 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $112.26 | 1.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $106.79 | 1.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $105.80 | 1.8% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $103.55 | 1.8% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $92.72 | 1.6% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.66 | 1.5% | 3 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $44.72 | 0.8% | 2 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $25.23 | 0.4% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $25.01 | 0.4% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.00 | 0.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.67 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,813.53 | 181 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $734.50 | 28 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $619.37 | 27 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $512.71 | 12 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $437.62 | 7 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $315.06 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $311.85 | 9 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $286.69 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $258.32 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $256.10 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $240.47 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $229.14 | 8 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $225.95 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $192.27 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $186.79 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $182.74 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $148.94 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $148.83 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $132.47 | 5 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $131.44 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $126.44 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $126.28 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $117.01 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $113.35 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $112.26 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $111.17 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $105.80 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $103.55 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $97.86 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $92.72 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $88.66 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $51.26 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.45 | 2 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $44.72 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 171 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 143 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 202 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
143 | 24 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
143 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
202 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
171 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 509 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 479 | 101 |
| Losartan Potassium | Losartan Potassium | 286 | 53 |
| Omeprazole | Omeprazole | 263 | 55 |
| Metformin Hcl | Metformin Hcl | 249 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 212 | 33 |
| Ozempic | Semaglutide | 202 | 27 |
| Januvia | Sitagliptin Phosphate | 192 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 33 |
| Gemtesa | Vibegron | 171 | 28 |
| Lisinopril | Lisinopril | 160 | 28 |
| Gabapentin | Gabapentin | 147 | 25 |
| Linzess | Linaclotide | 143 | 24 |
| Glimepiride | Glimepiride | 142 | 29 |
| Simvastatin | Simvastatin | 135 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 117 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 23 |
| Valsartan | Valsartan | 104 | 27 |
| Eliquis | Apixaban | 99 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 18 |
| Jardiance | Empagliflozin | 95 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 18 |
| Meloxicam | Meloxicam | 78 | 21 |
| Azithromycin | Azithromycin | 77 | 54 |
| Atenolol | Atenolol | 72 | suppressed |
| Glipizide | Glipizide | 70 | 12 |
| Vascepa | Icosapent Ethyl | 65 | 13 |
| Carvedilol | Carvedilol | 64 | 14 |
| Tradjenta | Linagliptin | 63 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 15 |
| Farxiga | Dapagliflozin Propanediol | 59 | 12 |
| Hydrocortisone | Hydrocortisone | 56 | 18 |
| Furosemide | Furosemide | 54 | suppressed |
| Novolog Flexpen | Insulin Aspart | 53 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 52 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | suppressed |
| Ibuprofen | Ibuprofen | 50 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Rybelsus | Semaglutide | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Clotrimazole | Clotrimazole | 34 | 11 |
| Naproxen | Naproxen | 34 | 11 |
| Promethazine Hcl | Promethazine Hcl | 33 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Restasis | Cyclosporine | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 24 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Dermacinrx Lidocan | Lidocaine | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Brinzolamide | Brinzolamide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Verquvo | Vericiguat | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,813.53 · 181 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, BREZTRI, CAPVAXIVE, CREON, Cologuard Collection Kit, DUPIXENT, EDARBI, FARXIGA, FREESTYLE LIBRE, GEMTESA, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PANCREAZE, PAXLOVID, QULIPTA, RECORLEV, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, Wegovy, YUPELRI, ZENPEP, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error